A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT05347225
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Hematological Malignancies

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nemtabrutinib — DRUG
    Nemtabrutinib tablets will be administered orally QD.

Study Details

The purpose of this study is to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of oral nemtabrutinib in Chinese participants at least 18 years of age who have Relapsed/Refractory hematologic malignancies.

Key Dates

Start date
Jun 9, 2022
Status verified
Apr 2026
Primary completion
Apr 30, 2027
Completion
Dec 29, 2028

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nemtabrutinib
    Participants receive nemtabrutinib at specified dose orally once daily (QD) until progressive disease (PD) or discontinuation.

Primary Outcome Measure

Number of Participants who Experience Adverse Events (AEs) [ Time Frame: Up to ~ 35 months ]

Related Studies